PT -期刊文章盟岩漠Satoshi AU -墙ase, Kimihiko AU - Tabara, Yasuharu AU - Minami, Takuma AU - Takahashi, Naomi AU - Nakatsuka, Yoshinari AU - Takeyama, Hirofumi AU - Hirai, Toyohiro AU - Matsuda, Fumihiko AU - Handa, Tomohiro AU - Chin, Kazuo TI - Impact of alpha-1 antitrypsin level on longitudinal lung function change: The Nagahama Study AID - 10.1183/13993003.congress-2019.PA2025 DP - 2019 Sep 28 TA - European Respiratory Journal PG - PA2025 VI - 54 IP - suppl 63 4099 - //www.qdcxjkg.com/content/54/suppl_63/PA2025.short 4100 - //www.qdcxjkg.com/content/54/suppl_63/PA2025.full SO - Eur Respir J2019 Sep 28; 54 AB - Background: Systemic inflammation can be associated with an accelerated decrease in pulmonary function in the general population. Alpha-1 antitrypsin (AAT) is a major protease inhibitor and its deficiency is one of the most common risk factors for developing early onset emphysema and chronic obstructive pulmonary disease. Recently, AAT has been recognized as a systemic inflammation marker. However, the association between AAT levels and longitudinal forced expiratory volume in one second (FEV1) changes has been unknown in the general population.Aims and Objectives: To examine the association between baseline AAT levels and longitudinal FEV1 changes in a general population-based large-scale cohort study.Methods: This study included 9,053 Japanese participants (male 2,962; female 6,091), in whom 7,525 (male 2,397; female 5,128) were included in the longitudinal analysis. The change in FEV1 was calculated by dividing the difference between the baseline and follow-up by follow-up periods (years). The change in FEV1 was categorized into two groups: rapid decline (change in FEV1 <–90mL/year) and non-rapid decline (change in FEV1 ≥–90mL/year).Results: Follow-up period was 1815 ± 135 days. FEV1 decreased by 34.2 ± 0.6 ml/year during the follow-up period. There were 862 (11.5%) participants with the rapid decline in FEV1. The elevation of baseline AAT levels was independently associated with the rapid decline in FEV1 (odds ratio = 1.09; 95% confidence interval = 1.04–1.14; p = 0.0004), although baseline AAT levels were not associated with baseline FEV1.Conclusions: The present findings imply that baseline AAT levels might become a new predicting factor for longitudinal FEV1 decline.FootnotesCite this article as: European Respiratory Journal 2019; 54: Suppl. 63, PA2025.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).